Pfizer Receives Chinese Clinical Approval for Two Trispecific Antibodies Targeting Moderate-to-Severe Atopic Dermatitis

According to the Zhijing Finance APPOn June 13, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that Pfizer (PFE.US) has received clinical approval for two Class 1 new drugs, both intended for the treatment of moderate to severe atopic dermatitis in adults. According to publicly available information from Pfizer, these two products are trispecific antibodies and new molecular entities in the company's inflammation and immunology pipeline. PF-07264660 is an anti-IL-4/IL-13/IL-33 tri-specific antibody, and PF-07275315 is an anti-IL-4/IL-13/TSLP tri-specific antibody. Both products are currently in international...Within the scope, all are in Phase 2 clinical stage.

According to publicly available information from Pfizer, the two trispecific antibodies, PF-07264660 and PF-07275315, can more effectively block the IL-4/IL-13 signaling pathway while producing broader effects by inhibiting TSLP, or further suppressing pruritus by inhibiting the IL-33 pathway, which is expected to yield better therapeutic outcomes for atopic dermatitis.